Clinical trial · Interventional
Spectral CT Combined With MSI for Predicting Regional Lymph Node Metastasis in Gastric Cancer
NCT07565818CI-TRIAL-00110190active not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study prospectively collected spectral CT imaging data and clinical information related to gastric cancer, evaluated the diagnostic efficacy of its image quality for regional lymph nodes in gastric cancer, and explored its application value in the N staging of gastric cancer with different MSI statuses, so as to provide a more accurate evidence for clinical diagnosis, promote the development of individualized treatment for gastric cancer, and ultimately improve the prognosis of patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| o explore the value of spectral CT in the diagnosis and treatment of gastric cancer with different MSI statuses | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Spectral CT combined with MSI for predicting regional lymph node metastasis in gastric cancer
- description
- Medical images and clinical data related to gastric cancer were prospectively collected using a Philips Quark CT scanner, and its diagnostic accuracy and clinical application value in gastric cancer patients with different MSI statuses were evaluated to achieve accurate staging of gastric cancer. Patients diagnosed with gastric cancer at Yunnan Cancer Hospital from August 2025 to December 2026 were consecutively enrolled. After undergoing Philips Quark CT scanning, the N stage of gastric cancer was independently assessed by two radiologists, and statistical analysis was subsequently performed for the final results.
- interventionNames
- Diagnostic Test: o explore the value of spectral CT in the diagnosis and treatment of gastric cancer with different MSI statuses
Primary outcomes (1)
- measure
- Pathological N stage
- timeFrame
- 1 day
- description
- The lymph node status confirmed by surgical pathology was used as the reference standard
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * (a)Patients with gastric adenocarcinoma confirmed by histopathological biopsy and definite microsatellite status determined by immunohistochemistry (IHC); * (b)Abdominal dual-phase Quark CT scanning was performed within 2 weeks before surgery; * (c)aged ≥ 18 years old Exclusion Criteria: * (a)Combined with other primary tumors; * (b) The image quality does not meet the diagnostic criteria; * (c)Those who cannot tolerate CT examination.
References
Publications (0)
Data not yet available
No reference posted for this study.